Thursday, Oct. 17, 2024 Promising NIAID-Funded Antimalarial Treatment Based on Marine Sponge This colorized scanning electron micrograph shows a red blood cell infected with malaria parasites (blue). Image: NIAID NIAID-funded researchers have shown that a promising antimalarial treatment is effective against both drug-sensitive and drug-resistant malaria parasites in laboratory and mouse studies. The experimental treatment, MED6-189, is a synthetic drug that is based on a compound found in marine sponges. The study, published in Science, primarily comes from researchers at the University of California-Riverside, UC-Irvine, and the Yale School of Medicine. MED6-189, the researchers showed, disrupts the lifecycle of the parasite, slows its growth, and kills it. The research team is hoping to gain approval to test the treatment in a Phase 1 clinical trial to evaluate it for safety and side effects. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107